Idéal Investisseur
Français English
CAC 40 : Market closed
8 365,01 pts
-0.05%


Last updated : 16/11/2026 - 17h14
🏠 Home   ➤    Stock news

Sanofi shares break through €87.98 and reach a 250-session high

The pharmaceutical company extends its strong rebound in a virtually stable CAC 40. The stock passes a level monitored for several weeks and climbs to the top of the index ranking.


Sanofi shares break through €87.98 and reach a 250-session high

A breakout that lifts the stock beyond its levels of the year

Sanofi gains 0.95% to €88.43, ranking among the top of the CAC 40, while the index rises only 0.04%.

During the session, the stock broke upward through €87.98, which corresponds to its highest level of the past 30, 150 and 250 sessions. This former resistance now becomes support, and the next round level is at €90.

The move extends a marked rebound: +22.55% over one month and +5.6% over one week. The RSI at 82 signals an overbought configuration, while the price remains 9.6% above the MM20 moving average, at €80.68. The 250-session high had already been mentioned on Thursday, before the stock surpassed it today.

A valuation of 9.9 times expected earnings, following raised targets

This rebound follows a third quarter with a 14.3% increase, published on October 30, during which the group raised its 2026 targets. Following this sequence, the stock trades at approximately 9.9 times current-year earnings and 9.4 times next-year earnings, according to the consensus of the analysts surveyed.

Expected earnings per share growth stands at +6.4%. Over twelve months, performance remains slightly negative at -1.3%, which places the recent rebound in a catch-up context. The next technical level identified is the €90 mark, while the €87.98 level broken today now constitutes the reference point below the price.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Pharmacie, vaccins et santé animale


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 36 550 millions d'euros
  • Quarterly revenue: 36 550 millions d'euros
  • Revenue growth: 13,1 %
  • Net income: 4 979 millions d'euros
  • Free cash flow: 6 993 millions d'euros
  • 12 201 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours